In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease. In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities. In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients. In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options. Experts at ESMO Congress 2024 discuss novel therapies for castration-resistant prostate cancer. Experts review the CONTACT-02 trial as well as the Decipher score utilized in the STAMPEDE trial. The roundtable of experts discuss the realities of the SPLASH trial's hazard ratio and overall survival results. At ESMO 2024, experts discuss androgen-deprivation therapy in HSPC as well as the ARANOTE trial. Experts at ESMO 2024 discuss the implications and insights associated with the Peace III trial. Experts discuss mHSPC discuss risk stratification, developed novel approaches for treatment, and treatment sequencing. The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration. The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies. The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education. The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen. The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies. The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans. The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC. The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens. The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation. The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.